X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with TTK HEALTHCARE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs TTK HEALTHCARE - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA TTK HEALTHCARE ALEMBIC PHARMA/
TTK HEALTHCARE
 
P/E (TTM) x 29.0 50.0 58.1% View Chart
P/BV x 6.6 9.2 71.9% View Chart
Dividend Yield % 0.7 0.3 225.3%  

Financials

 ALEMBIC PHARMA   TTK HEALTHCARE
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
TTK HEALTHCARE
Mar-14
ALEMBIC PHARMA/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs792663 119.3%   
Low Rs443399 111.0%   
Sales per share (Unadj.) Rs167.0535.6 31.2%  
Earnings per share (Unadj.) Rs38.215.9 239.3%  
Cash flow per share (Unadj.) Rs42.020.0 209.7%  
Dividends per share (Unadj.) Rs4.004.00 100.0%  
Dividend yield (eoy) %0.60.8 86.0%  
Book value per share (Unadj.) Rs84.9137.6 61.7%  
Shares outstanding (eoy) m188.527.77 2,426.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.71.0 372.7%   
Avg P/E ratio x16.233.3 48.6%  
P/CF ratio (eoy) x14.726.5 55.4%  
Price / Book Value ratio x7.33.9 188.4%  
Dividend payout %10.525.1 41.8%   
Avg Mkt Cap Rs m116,3834,127 2,819.7%   
No. of employees `000NA1.7 0.0%   
Total wages/salary Rs m4,214607 694.7%   
Avg. sales/employee Rs ThNM2,436.7-  
Avg. wages/employee Rs ThNM355.2-  
Avg. net profit/employee Rs ThNM72.5-  
INCOME DATA
Net Sales Rs m31,4874,162 756.6%  
Other income Rs m5561 90.0%   
Total revenues Rs m31,5424,223 746.9%   
Gross profit Rs m10,060197 5,103.9%  
Depreciation Rs m72232 2,277.9%   
Interest Rs m3730 123.1%   
Profit before tax Rs m9,356197 4,756.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,16073 2,967.3%   
Profit after tax Rs m7,194124 5,806.5%  
Gross profit margin %31.94.7 674.6%  
Effective tax rate %23.137.0 62.4%   
Net profit margin %22.83.0 767.5%  
BALANCE SHEET DATA
Current assets Rs m15,0661,629 925.0%   
Current liabilities Rs m7,6741,058 725.5%   
Net working cap to sales %23.513.7 171.1%  
Current ratio x2.01.5 127.5%  
Inventory Days Days6730 224.9%  
Debtors Days Days4134 121.0%  
Net fixed assets Rs m8,237556 1,480.8%   
Share capital Rs m37778 485.2%   
"Free" reserves Rs m15,416878 1,755.3%   
Net worth Rs m16,0051,069 1,496.8%   
Long term debt Rs m0159 0.0%   
Total assets Rs m24,5942,399 1,025.0%  
Interest coverage x255.27.6 3,367.9%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.31.7 73.8%   
Return on assets %29.46.4 458.7%  
Return on equity %44.911.6 387.9%  
Return on capital %58.718.5 318.0%  
Exports to sales %55.70.8 7,051.0%   
Imports to sales %10.41.4 744.3%   
Exports (fob) Rs m17,55133 53,345.9%   
Imports (cif) Rs m3,28358 5,631.2%   
Fx inflow Rs m17,81133 54,135.3%   
Fx outflow Rs m5,31863 8,415.9%   
Net fx Rs m12,493-30 -41,243.0%   
CASH FLOW
From Operations Rs m9,304127 7,349.1%  
From Investments Rs m-3,105-146 2,126.6%  
From Financial Activity Rs m-1,95922 -8,945.7%  
Net Cashflow Rs m4,2403 169,600.0%  

Share Holding

Indian Promoters % 74.1 65.4 113.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 3.7 78.4%  
FIIs % 9.1 5.2 175.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 25.8 53.9%  
Shareholders   49,328 12,723 387.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   FDC LTD.  ALEMBIC LTD  WYETH LTD  AJANTA PHARMA  SUVEN LIFE  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Firm US Markets; Sun Pharma, Software Stocks & Other Top Cues to Sway the Markets Today(Pre-Open)

Indian share markets finished the previous trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

A New Quest for the Stock Market's MOST Profitable Ideas...(Smart Contrarian)

Feb 23, 2018

If you want to receive the best ideas in the Indian stick markets...you need to heed this important announcement.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS